Evaluating the benefit/risk and safety profile of PCSK9 inhibitors - Clinical and economic implications
Congress Presentation
About the speaker
Doctor Christie Ballantyne
5 more presentations in this session
The need for urgency in treating hyperlipidemia in post-ACS patients
Speaker: Professor F. Schiele (Besancon, FR)
Enriching the PCSK9i evidence - The most recent analyses from ODYSSEY OUTCOMES
Speaker: Professor J. Jukema (Leiden, NL)
Panel discussion
Speaker: Professor J. Jukema (Leiden, NL) Professor F. Schiele (Besancon, FR) Doctor C. Ballantyne (Houston, US)
Conclusion and key takeaways
Speaker: Professor J. Jukema (Leiden, NL) Professor F. Schiele (Besancon, FR) Doctor C. Ballantyne (Houston, US)
Access the full session
Evolving scientific evidence with PCSK9 inhibitors based on ODYSSEY outcomes
About the event
ESC 365 is supported by
